| 1 |
Huang XZ, Pang MJ, Li JY, Chen HY, Sun JX, Song YX, Ni HJ, Ye SY, Bai S, Li TH, Wang XY, Lu JY, Yang JJ, Sun X, Mills JC, Miao ZF, Wang ZN. Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis. Nat Commun 2023;14:822. [PMID: 36788228 DOI: 10.1038/s41467-023-36310-9] [Reference Citation Analysis]
|
| 2 |
Kawakami H, Sunakawa Y, Inoue E, Matoba R, Noda K, Sato T, Suminaka C, Yamaki M, Sakamoto Y, Kawabata R, Ishiguro A, Akamaru Y, Kito Y, Yabusaki H, Matsuyama J, Takahashi M, Makiyama A, Hayashi H, Chamoto K, Honjo T, Nakagawa K, Ichikawa W, Fujii M. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial. Eur J Cancer 2023;184:10-20. [PMID: 36889037 DOI: 10.1016/j.ejca.2023.02.003] [Reference Citation Analysis]
|
| 3 |
Aoki M, Kadowaki S, Takahashi N, Suzuki T, Oshima K, Ando T, Yamamoto Y, Kawakami K, Kito Y, Matsumoto T, Shimozaki K, Miyazaki Y, Yamaguchi T, Nagase M, Tamura T, Amanuma Y, Esaki T, Miura Y, Akiyoshi K, Baba E, Makiyama A, Negoro Y, Nakashima K, Sugimoto N, Nagashima K, Shoji H, Boku N. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan. Gastric Cancer 2023;26:132-44. [PMID: 36316527 DOI: 10.1007/s10120-022-01349-y] [Reference Citation Analysis]
|
| 4 |
Wang MX, Gao SY, Yang F, Fan RJ, Yang QN, Zhang TL, Qian NS, Dai GH. Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression? World J Clin Oncol 2022; 13(9): 729-737 [DOI: 10.5306/wjco.v13.i9.729] [Reference Citation Analysis]
|
| 5 |
Liang H, Li Z, Huang Z, Wu C, Qiu Y, Liang Y, Chen X, Li F, Xu Z, Li G, Liu H, Zhao L. Prognostic characteristics and clinical response to immunotherapy targeting programmed cell death 1 for patients with advanced gastric cancer with liver metastases. Front Immunol 2022;13:1015549. [DOI: 10.3389/fimmu.2022.1015549] [Reference Citation Analysis]
|
| 6 |
Kepenekian V, Bhatt A, Péron J, Alyami M, Benzerdjeb N, Bakrin N, Falandry C, Passot G, Rousset P, Glehen O. Advances in the management of peritoneal malignancies. Nat Rev Clin Oncol 2022. [PMID: 36071285 DOI: 10.1038/s41571-022-00675-5] [Reference Citation Analysis]
|
| 7 |
Zhao Z, Bian J, Zhang J, Zhang T, Lu X. Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis. Front Oncol 2022;12:843707. [DOI: 10.3389/fonc.2022.843707] [Reference Citation Analysis]
|
| 8 |
Evrard C, Aparicio T, Soularue E, Le Malicot K, Desramé J, Botsen D, El Hajbi F, Gonzalez D, Lepage C, Bouché O, Tougeron D, on behalf of the DURIGAST—PRODIGE 59 Investigators/Collaborators. Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. Biomedicines 2022;10:1211. [DOI: 10.3390/biomedicines10051211] [Reference Citation Analysis]
|
| 9 |
Ruiz Hispán E, Pedregal M, Cristobal I, García-Foncillas J, Caramés C. Immunotherapy for Peritoneal Metastases from Gastric Cancer: Rationale, Current Practice and Ongoing Trials. J Clin Med 2021;10:4649. [PMID: 34682772 DOI: 10.3390/jcm10204649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
